Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Edico Genome Launches DRAGEN Complete Suite On AWS Marketplace, Including Enhanced Second-Generation Germline And Somatic Pipelines


LAS VEGAS, Nov. 30, 2017 /PRNewswire/ -- Today at AWS re:Invent, Edico Genome revealed its DRAGEN Complete Suite (DRAGEN CS) on AWS Marketplace, a comprehensive package of pipelines that enables AWS users to access all of DRAGEN's applications for next-generation sequencing (NGS) data analysis in one click. Pieter van Rooyen, Ph.D., president and CEO at Edico Genome, and Rami Mehio, vice president of engineering at Edico Genome, will discuss DRAGEN CS during a panel titled, "FPGA Accelerated Computing Using Amazon EC2 F1 Instances," held today at 5:45 p.m. PT at re:Invent.

Edico Genome's logo (PRNewsFoto/Edico Genome)

DRAGEN CS includes second-generation versions of the DRAGEN Germline and Somatic Pipelines, which feature enhanced mapping and aligning algorithms and greatly improved variant calling. The new variant calling algorithms are able to better distinguish real variants from errors introduced in sample preparation and sequencing. The DRAGEN Germline V2 Pipeline was recognized as a top performer in the PrecisionFDA Hidden Treasures ? Warm Up Challenge in October 2017, receiving the top score in five of six accuracy metrics among 30 participants. 

"By utilizing sample-specific prep and sequencer-error modeling, DRAGEN is able to identify real variants with even greater precision, resulting in enhanced accuracy and accelerated analysis speeds," said Mr. Mehio. "In fact, DRAGEN's INDEL calling, which usually presents a greater challenge for analysis tools than single nucleotide polymorphisms, demonstrated the highest level of accuracy among pipelines identifying hidden variants in the recent PrecisionFDA challenge. With the integration of these cutting-edge algorithms, DRAGEN is now the top performer in accuracy as well as speed."

DRAGEN CS contains tools for all pipeline steps, including mapping/aligning, position sorting, duplicate marking and variant calling. The application accepts sequencing data inputs in BCL, FASTQ, and BAM/CRAM formats, and features BCL conversion, download and upload streaming, and compressed hash tables for a more streamlined and efficient workflow. The Complete Suite offers the following pipelines:

"Edico Genome's goal is to simplify NGS for our users ? arming them with industry leading speeds, accuracy and scalability through an easy-to-use interface to streamline their work," said Dr. van Rooyen. "Our engineering team is perpetually working on new algorithms that rapidly and accurately analyze genomic data -- enabling clinicians to get to diagnoses faster, and researchers to get to results more rapidly -- and we look forward to releasing new offerings in the coming months."

DRAGEN leverages field programmable gate arrays (FPGAs) to rapidly accelerate secondary analysis of NGS data both onsite and in the Cloud via AWS Marketplace. Edico Genome recently demonstrated the speed and scalability of DRAGEN on the AWS Marketplace by deploying 1,000 Amazon EC2 F1 instances to analyze 1,000 whole human genome sequences in only 2 hours and 25 minutes, setting the GUINNESS WORLD RECORDSTM title for Fastest time to analyze 1,000 human genomes.

A one-day trial for use of exome and genome pipelines is available to new customers. To learn more about DRAGEN on AWS Marketplace, visit http://edicogenome.com/awsmarketplace/.

Contact Edico Genome

Stephanie Black
Marketing Manager
(858) 722-3694
[email protected] 

Monica May
Canale Communications
(619) 849-5383
[email protected]

About Edico Genome

The use of next-generation sequencing is growing at an unprecedented pace, creating a need for easy to implement infrastructure that enables rapid, accurate and cost-effective processing and storage of this big data. Edico Genome has created a patented, end-to-end platform solution for analysis of next-generation sequencing data, DRAGENtm, which speeds whole genome data analysis from hours to minutes while maintaining high accuracy and reducing costs. Top clinicians and researchers are utilizing the platform to achieve faster diagnoses for critically ill newborns, cancer patients and expecting parents waiting on prenatal tests, and faster results for scientists and drug developers. For more information, visit www.EdicoGenome.com or follow @EdicoGenome.

 

SOURCE Edico Genome


These press releases may also interest you

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...

at 17:00
The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has approved a 2024 premium dividend of approximately $14.7 million, bringing the total of declared dividends to date to $470 million....

at 17:00
Northern Virginia Oral, Maxillofacial & Implant Surgery ("NOVA OMS") has learned of a data security incident that may have impacted data belonging to certain patients and guarantors. On October 5, 2023, NOVA OMS became aware of unusual activity on...

at 17:00
The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to...



News published on and distributed by: